Compare ClearPoint Neuro Inc (CLPT) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Synchrony Financial — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while Synchrony Financial trades at $73.68 (market cap $24.78B). The key difference: Synchrony Financial is far larger — about 51.8× ClearPoint Neuro Inc's market cap, and Synchrony Financial pays a 1.63% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | SYF | |
|---|---|---|
Market Cap | $478.63M | $24.78B |
Sector | Health | Financials |
52-Week High | $29.60 | $88.47 |
52-Week Low | $8.66 | $63.78 |
Enterprise Value | $506.63M | — |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
SYF trades at $73.21, up 1.06% today, with a bearish technical signal but strong fundamentals. The stock shows a low P/E of 7.63 and robust profitability with a 24.06% net income margin. Recent earnings beats and a $0.30 dividend highlight operational strength, while analyst consensus is bullish with a $86.38 price target.
Outlook remains positive due to earnings momentum and undervaluation, but risks include economic sensitivity and technical weakness. The stock offers value with upside potential, though investors should monitor loan performance and interest rate impacts on financial results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
